PAXLOVID®▼ (nirmatrelvir; ritonavir) is authorised in Ireland

Authorisation has been granted in the EU for PAXLOVID® for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Read the PAXLOVID® PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Ensuring the Authenticity of PAXLOVID®

Authentic PAXLOVID® from Pfizer will include the Pfizer name on the outer carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. Nirmatrelvir tablets are pink, oval-shaped and debossed with 'PFE' on one side and '3CL' on the other side. Ritonavir tablets are white to off white, capsule shaped, and debossed with 'H' on one side and 'R9' on the other side.

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.

The outer carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

If you suspect the PAXLOVID® you have received may be counterfeit, please report this to your local representative on 1800 633 363.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

ADVERSE EVENT REPORTING

If you wish to report an adverse event please email Pfizer at GBR.AEReporting@Pfizer.com or contact Pfizer at 1800 633 363. If you have a medical information inquiry please go to www.PfizerMedicalInformation.ie or email medical.information@pfizer.com or contact Pfizer at 1800 633 363. If you have a product quality complaint please email medical.information@pfizer.com or contact Pfizer at 1800 633 363.

PP-C1D-IRL-0011; Date of Preparation July 2024